Matritech, Inc.'s NMP22(R) BladderChek(R) Test will be Featured in Presentations at the American Urological Association Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Matritech (Amex: MZT), a leading developer and marketer of protein-based diagnostic products for the early detection of cancer, announced today that the NMP22® BladderChek® Test will be included in a plenary session State-of-the-Art lecture and two discussed poster presentations May 21-22, 2007 at the American Urological Association (AUA) annual meeting in Anaheim, California. More than 10,000 urologists and healthcare professionals are expected to attend the conference.